On April 11, 2020, The Infectious Disease Society of America (IDSA) published evidence-based rapid guidelines pertaining to COVID-19 treatment options. The IDSA has since updated those guidelines. This summary highlights the recommendations within those guidelines, as of May 3, 2020.
The complete guidelines, objectives, and methodologies can be found by clicking here.
Key Recommendations from the IDSA’s Multidisciplinary Panel
For patients hospitalized with COVID-19:
Hydroxychloroquine/chloroquine is recommended only in the context of a clinical trial.
Hydroxychloroquine/chloroquine plus azithromycin is recommended in the context of a clinical trial.
Lopinavir/ritonavir is recommended only in the context of a clinical trial.
Tocilizumab is recommended only in the context of a clinical trial.
Convalescent plasma is recommended only in the context of a clinical trial.
For patients hospitalized with COVID-19 pneumonia:
Corticosteroids are conditionally recommended (very low certainty of evidence).
For patients hospitalized with ARDS due to COVID-19:
Corticosteroids are recommended only in the context of a clinical trial.
In addition to the clinical recommendations listed above, the IDSA identified treatments that are currently undergoing evaluation, but require more data before a recommendation can be made:
HIV antivirals
Lopinavir-ritonavir combined with interferon beta or other antivirals
COVID-19 convalescent plasma for prophylaxis
Ribavirin
Oseltamivir
Intravenous immunoglobulin
Remdesivir
Stopping NSAIDs in patients with COVID-19
Stopping ACE inhibitors and ARBs for hypertension when a patient has COVID-19
Complete recommendation and treatment details are available here.